Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 18:13:04 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Calliditas - A cautious guide ahead of visible support later in 2024

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Calliditas - A cautious guide ahead of visible support later in 2024

2024-02-22 11:11:00

Apart from the new label, Tarpeyo is supported by a higher price and 50-51% growth in prescribers and patient enrollment. Calliditas is setting a cautious guide ahead of visible and improved private pay conversion in 2024. We expect Calliditas to take a more proactive approach to the 2024 guide as the launch progresses, with added support from both the OLE study and the KDIGO revision later in 2024. Our updated view is a base case valuation of SEK 270 (280) and a Bull Case of SEK 390 (415) and a Bear Case of SEK 70 (70).

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/